Success Metrics

Clinical Success Rate

66.7%

Based on 2 completed trials

Completion Rate

67%(2/3)

Active Trials

4(50%)

Results Posted

100%(2 trials)

Terminated

1(13%)

Phase Distribution

Ph phase_1

38%

Ph phase_2

50%

Ph phase_3

13%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution8 total trials

Phase 1Safety & dosage

3(37.5%)

Phase 2Efficacy & side effects

4(50.0%)

Phase 3Large-scale testing

1(12.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(4)

Completed(2)

Terminated(2)

Detailed Status

Active, not recruiting4

Completed2

Terminated1

Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

66.7%

Most Advanced

Phase 3

Trials by Phase

Phase 13 (37.5%)

Phase 24 (50.0%)

Phase 31 (12.5%)

Trials by Status

terminated113%

active_not_recruiting450%

withdrawn113%

completed225%

Recent Activity

4 active trials

Showing 5 of 8

active_not_recruitingphase_2

Study of Niraparib and TSR-042 in Recurrent Endometrial Cancer

NCT03016338

active_not_recruitingphase_2

TSR-042 as Maintenance Therapy for Patients With High-risk Locally Advanced Cervical Cancer After Chemo-radiation

NCT03833479

active_not_recruitingphase_1

TSR-042 in Addition to Standard of Care Definitive Radiation for Inoperable Endometrial Cancer

NCT03955978

completedphase_1

Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042

NCT03307785

active_not_recruitingphase_1

A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

NCT02817633

View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials

NCT03016338Phase 2

Study of Niraparib and TSR-042 in Recurrent Endometrial Cancer

Active Not Recruiting

NCT03833479Phase 2

TSR-042 as Maintenance Therapy for Patients With High-risk Locally Advanced Cervical Cancer After Chemo-radiation

Active Not Recruiting

NCT03955978Phase 1

TSR-042 in Addition to Standard of Care Definitive Radiation for Inoperable Endometrial Cancer

Active Not Recruiting

NCT03307785Phase 1

Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042

Completed

NCT02817633Phase 1

A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

Active Not Recruiting

NCT03574779Phase 2

A Study to Evaluate the Efficacy and Safety of Novel Treatment Combinations in Participants With Ovarian Cancer

Completed

NCT04274023Phase 2

Study on TSR-042 in Advanced Clear Cell Sarcoma

Terminated

NCT03806049Phase 3

Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer

Withdrawn

All 8 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 8